Internal medicine journal · 2026
Vitamin B6: too much, too little, too late? An analysis of sales trends in Australia from 2023 to 2025.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chan Wai-Jo Jocelin, Hunter Jennifer, Lee Vivian Yeukman, Cairns Rose, Mathews Slade, Harnett Joanna E
Аннотация
BACKGROUND: Peripheral neuropathy associated with vitamin B6 (pyridoxine) is dose and duration dependent. High-dose vitamin B6 products associated with adverse neurological effects are available in Australia, prompting recent regulatory action to reschedule products containing ≥50 mg pyridoxine to schedule 3 (pharmacist only).
AIMS: This study examined real-world consumer purchasing behaviours of vitamin B6 products in Australian pharmacies to identify high-risk purchasing patterns (e.g. large doses, multiple products, stockpiling behaviours).
METHODS: Sales data from the IQVIA Consumer Health Basket Database (1 August 2022-31 July 2025), representing ~75% of national pharmacy-based complementary medicines sales were analysed. Listed medicines on the Australian Register of Therapeutic Goods providing a daily dose of ≥5 mg total equivalent pyridoxine were included (n = 792). Analysis included unit sales, combined total maximum daily dosage per transaction and duplicate purchases as a proxy for ongoing use.
RESULTS: A total of 20.32 million products (≥5 mg) were sold across 15.8 million transactions. Products containing 10-49 mg dominated sales with 11.0 million (54.20%) unit sales, and ≥50 mg doses accounted for 3.40 million (16.75%) units and 3.4 million (21.63%) of all transactions. Multiple products or duplicate purchases occurred in 1.2 million (7.73%) and 1.58 million (9.17%) transactions respectively. Sales were otherwise stable, except for the 2023 withdrawal of >100 mg products.
CONCLUSION: Large volumes of vitamin B6 products containing doses above the recommended intake continue to be purchased in Australia, including through combinations of lower-dose products that will not be affected by proposed rescheduling. The implementation period for scheduling extends the potential for stockpiling, meaning that high-risk exposure will persist without strengthened risk communication.
AIMS: This study examined real-world consumer purchasing behaviours of vitamin B6 products in Australian pharmacies to identify high-risk purchasing patterns (e.g. large doses, multiple products, stockpiling behaviours).
METHODS: Sales data from the IQVIA Consumer Health Basket Database (1 August 2022-31 July 2025), representing ~75% of national pharmacy-based complementary medicines sales were analysed. Listed medicines on the Australian Register of Therapeutic Goods providing a daily dose of ≥5 mg total equivalent pyridoxine were included (n = 792). Analysis included unit sales, combined total maximum daily dosage per transaction and duplicate purchases as a proxy for ongoing use.
RESULTS: A total of 20.32 million products (≥5 mg) were sold across 15.8 million transactions. Products containing 10-49 mg dominated sales with 11.0 million (54.20%) unit sales, and ≥50 mg doses accounted for 3.40 million (16.75%) units and 3.4 million (21.63%) of all transactions. Multiple products or duplicate purchases occurred in 1.2 million (7.73%) and 1.58 million (9.17%) transactions respectively. Sales were otherwise stable, except for the 2023 withdrawal of >100 mg products.
CONCLUSION: Large volumes of vitamin B6 products containing doses above the recommended intake continue to be purchased in Australia, including through combinations of lower-dose products that will not be affected by proposed rescheduling. The implementation period for scheduling extends the potential for stockpiling, meaning that high-risk exposure will persist without strengthened risk communication.